NCT00839683已完成1 期
Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs
研究概览
简要总结
Phase A - To assess the effect of simvastatin on the pharmacokinetics (PK) of dapagliflozin and to determine the effect of dapagliflozin on the PK of simvastatin, when simvastatin and dapagliflozin are coadministered in healthy subjects. Phase B - To assess the effect of valsartan on the PK of dapagliflozin and to determine the effect of dapagliflozin on the PK of valsartan, when valsartan and dapagliflozin are coadministered in healthy subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
- •Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive. BMI = weight (kg)/[height (m)]2
排除标准
- •Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 12 weeks after the last dose of investigational product
- •Abnormal urinalysis at screening (repeat urinalysis may be allowed for positive hematuria in women)
- •Glucosuria at screening
- •Abnormal liver functions tests (ALT, AST or total bilirubin > 10% above ULN)
- •Presence of edema on physical exam
- •History of diabetes mellitus
- •History of heart failure
- •History of renal insufficiency
- •History of chronic or recurrent UTI (defined as 3 occurrences per year) or UTI in the past 3 months
- •History of recurrent (defined as 3 occurences per year) or recent vulvovaginal mycotic infections
- •Positive urine screen for drugs of abuse either at screening or before dosing
- •Positive blood screen for hepatitis C antibody, hepatitis C antibody, hepatitis B surface antigen, or HIV-1, -2 antibody
- •History of allergy to SGLT2 inhibitors or related compounds
- •History of any significant drug allergy (such as anaphylaxis or hepatotoxicity)
- •History of allergy or intolerance to valsartan or simvastatin (or related compounds)
- •Prior exposure to dapagliflozin, valsartan or simvastatin within 3 months of Day -1
- •Exposure to any investigational drug or placebo within 4 weeks of Day -1
- •Use of any prescription drugs within 4 weeks or over-the-counter acid controllers within 2 weeks prior to any study drug administration
- •Use of any other drugs, including over-the counter medications within 1 week and herbal preparations within 2 weeks prior to admission to the study facility
- •Use of an oral, injectable or implantable hormonal contraceptive agent within 3 months of Day -1
研究组 & 干预措施
valsartan
Active Comparator
干预措施: valsartan (Drug)
Dapagliflozin + valsartan
Active Comparator
干预措施: Dapagliflozin (Drug)
Dapagliflozin
Active Comparator
干预措施: Dapagliflozin (Drug)
simvastatin
Active Comparator
干预措施: simvastatin (Drug)
Dapagliflozin + simvastatin
Active Comparator
干预措施: Dapagliflozin (Drug)
Dapagliflozin + simvastatin
Active Comparator
干预措施: simvastatin (Drug)
Dapagliflozin + valsartan
Active Comparator
干预措施: valsartan (Drug)
结局指标
主要结局
Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs
时间窗: 72 hours post-dose
次要结局
- To assess the safety and tolerability of dapagliflozin when administered alone, with valsartan, or with simvastatin in healthy subjects(15 timepoints)
- To assess the safety and tolerability of the combination of dapagliflozin with valsartan, and the combination of dapagliflozin with simvastatin in healthy subjects(15 timepoints)
- To assess the effect of dapagliflozin on the PK of simvastatin acid (active metabolite of simvastatin), when coadministered in healthy subjects(15 timepoints)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy SubjectsType 2 Diabetes MellitusNCT00842556AstraZeneca18
已完成
1 期
Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy SubjectsDiabetes Mellitus, Type 2NCT00562250AstraZeneca11
已完成
1 期
Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus PatientsType 2 Diabetes MellitusNCT01055652AstraZeneca28
Unknown
1 期
Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mgT2DMNCT04544319LG Chem44
已完成
不适用
The study of dapagliflozin versus sitagliptin treatment efficacy on preventing cardiovascular risk factors in type 2 DM patients (DIVERSITY-CVR study)Type 2 Diabetes MellitusJPRN-UMIN000028014the Japan Society for Patient Reported Outcome (PRO)340